In a phase II umbrella trial, the VIKTORY trial, 715 gastric cancer patients underwent genomic sequencing and enrolled in the genomic matched cohort. Among the 715 patients, 25 (3.5%) patients harbored MET amplification and received savolitinib, a selective MET inhibitor. Tumor tissue and plasma ctDNA samples from the first three patients were obtained before treatment, during therapy, and at the time of progression.
News
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
- Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
- Anbogen Secures $12.5 Million USD in Series A Funding, Advancing Precision Oncology Drug Development
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation